This report was first published by Endpoints News. To see the original version, click here
GSK said on Wednesday that it is buying 35Pharma for $950 million, picking up the Canadian biotech’s pulmonary hypertension drug program — and potentially dipping its toes into investigating weight loss drugs that avoid muscle loss.
At the heart of the deal is a drug called HS235, which has completed studies in healthy subjects and is about to enter clinical trials. The upcoming trials will focus on pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
您已阅读22%（622字），剩余78%（2269字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。